Cytokinetics (CYTK)

Jan 13, 2025, 7:30 AM EST - 4 days ago

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

Jan 6, 2025, 4:00 PM EST - 11 days ago

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:00 PM EST - 14 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dec 31, 2024, 8:30 AM EST - 17 days ago

Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution

Dec 23, 2024, 7:30 AM EST - 25 days ago

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Dec 20, 2024, 12:00 AM EST - 4 weeks ago

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

Dec 3, 2024, 4:00 PM EST - 6 weeks ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2024, 7:30 AM EST - 6 weeks ago

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

Dec 2, 2024, 4:00 PM EST - 6 weeks ago

Cytokinetics to Participate in December Investor Conferences

Dec 2, 2024, 7:30 AM EST - 6 weeks ago

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Nov 19, 2024, 3:26 AM EST - 2 months ago

Bayer acquires rights to Cytokinetics' heart drug in Japan

Nov 19, 2024, 2:30 AM EST - 2 months ago

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

Nov 16, 2024, 9:00 AM EST - 2 months ago

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

Nov 16, 2024, 9:00 AM EST - 2 months ago

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

Nov 11, 2024, 7:30 AM EST - 2 months ago

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

Nov 6, 2024, 7:58 PM EST - 2 months ago

Cytokinetics, Incorporated (CYTK) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:00 PM EST - 2 months ago

Cytokinetics Reports Third Quarter 2024 Financial Results

Oct 23, 2024, 4:00 PM EDT - 3 months ago

Cytokinetics to Announce Third Quarter Results on November 6, 2024

Oct 16, 2024, 7:30 AM EDT - 3 months ago

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day

Sep 30, 2024, 9:20 AM EDT - 3 months ago

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting

Sep 27, 2024, 11:00 AM EDT - 4 months ago

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

Sep 24, 2024, 7:30 AM EDT - 4 months ago

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program

Sep 19, 2024, 4:00 PM EDT - 4 months ago

Cytokinetics Announces Upcoming Presentations at the HCMS Scientific Sessions and the HFSA Annual Scientific Meeting

Sep 9, 2024, 1:11 PM EDT - 4 months ago

Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study

Sep 9, 2024, 7:30 AM EDT - 4 months ago

Cytokinetics Announces Data From Phase 1 Study of CK-4021586

Sep 5, 2024, 4:00 PM EDT - 4 months ago

Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting

Sep 1, 2024, 4:27 AM EDT - 4 months ago

Cytokinetics Presents New Data Related to the Safety and Long-Term Use of Aficamten at the European Society of Cardiology Congress 2024

Sep 1, 2024, 3:51 AM EDT - 4 months ago

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the European Society of Cardiology Congress 2024

Aug 29, 2024, 4:00 PM EDT - 5 months ago

Cytokinetics to Participate in September Investor Conferences

Aug 13, 2024, 4:07 PM EDT - 5 months ago

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Aug 9, 2024, 9:17 PM EDT - 5 months ago

Cytokinetics, Incorporated (CYTK) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:00 PM EDT - 5 months ago

Cytokinetics Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:30 AM EDT - 6 months ago

Cytokinetics Announces Call for Proposals for Corporate Giving Program

Jul 25, 2024, 4:00 PM EDT - 6 months ago

Cytokinetics to Announce Second Quarter Results on August 8, 2024

Jul 24, 2024, 8:00 AM EDT - 6 months ago

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

Jun 17, 2024, 7:30 AM EDT - 7 months ago

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

May 29, 2024, 4:00 PM EDT - 8 months ago

Cytokinetics to Participate in June Investor Conferences

May 29, 2024, 2:45 PM EDT - 8 months ago

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

ARVN AXSM NTLA NVS PFE REGN VKTX

May 28, 2024, 4:00 PM EDT - 8 months ago

Cytokinetics Announces Closing of Public Offering of Common Stock

May 22, 2024, 11:30 PM EDT - 8 months ago

Cytokinetics Announces Pricing of Public Offering of Common Stock

May 22, 2024, 4:02 PM EDT - 8 months ago

Cytokinetics Announces Proposed Public Offering of Common Stock

May 22, 2024, 4:00 PM EDT - 8 months ago

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 17, 2024, 7:30 AM EDT - 8 months ago

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

May 15, 2024, 7:30 AM EDT - 8 months ago

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

May 13, 2024, 9:33 AM EDT - 8 months ago

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

May 13, 2024, 9:33 AM EDT - 8 months ago

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

May 9, 2024, 12:06 AM EDT - 9 months ago

Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:00 PM EDT - 9 months ago

Cytokinetics Reports First Quarter 2024 Financial Results

May 8, 2024, 7:30 AM EDT - 9 months ago

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

May 8, 2024, 7:30 AM EDT - 9 months ago

Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586